AstraZeneca’s Tagrisso Plus Chemotherapy Receives Health Canada’s Approval to Treat Advanced Lung Cancer
Shots:
- Health Canada has approved Tagrisso + pemetrexed and platinum-based chemotherapy as a 1L treatment of locally advanced or metastatic EGFRm NSCLC, based on P-III (FLAURA2) study
- The P-III (FLAURA2) study of Tagrisso (80mg, oral, QD) + CT [pemetrexed (500mg/m^2) + cisplatin (75mg/m^2) or carboplatin (AUC5), Q3W] followed by Tagrisso with pemetrexed maintenance (Q3W) in locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC patients (n=557)
- Study depicted 38% PFS & 25.5mos. vs 16.7mos. mPFS as per investigator evaluation. OS evaluation is underway
Ref: Astrazeneca | Image: Astrazeneca
Related News:- AstraZeneca’s Tagrisso Plus Chemotherapy Receives NMPA’s Approval to Treat EGFR-Mutated Advanced Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
